Print Email  

End Duchenne Grant Award Program

PPMD has developed the EndDuchenne Grant Award Program in partnership with the National Institutes of Health (NIH) in an effort to ensure continuation of promising research and translation to human studies. The EndDuchenne Grant Award Program is a bridge grant provided by PPMD to promising research projects that receive scores beyond the current funding paylines of the National Institutes of Health (NIH) Institutes and Centers supporting Duchenne muscular dystrophy research. The goal and hope of this grant program is that bridge funding would accelerate promising research forward and enhance the success of competition for federal dollars toward new treatment development for Duchenne muscular dystrophy.

Specific Features

  1. Any NIH grant type mechanisms is acceptable to this program if the work scope of the research is directly applicable to the development of new treatments for Duchenne muscular dystrophy. Only applications that are translational in nature, that is, applications that are designed to move scientific discoveries at any stage of preclinical development to new therapeutic development will be considered for this program.
  2. Awards are made for up to one year with the expectation that the grantee will submit a revised application to the NIH before the end of the PPMD funded bridge year.
  3. Applicants can request up to $150,000, not to exceed the amount of the first year direct costs budget as contained within the NIH application. Indirect costs of 5% are supported in this program.
  4. PPMD will conduct an independent review of the research proposal for funding consideration. The review committee will make recommendations to PPMD for funding of all or part of the research proposal for an EndDuchenne Grant award. 
  5. Review of applications for EndDuchenne Grant award will occur three times per year to coincide with NIH grant review cycles, following each NIH review cycle, provided applications are identified for this program.


An applicant seeking support for this program must be employed at a for-profit or non-profit organization or institution and have submitted and received a complete review of an application to the NIH directed toward translation of research into human clinical studies specific for Duchenne muscular dystrophy within the last year. The applicant must have the resources to conduct the proposed research project and the organization/institution must have appropriate grant administrative capacities for the handling and disbursing of research funds.

Application Process

The EndDuchenne Grant Award Program process builds from the NIH grant review process. Applicants are requested to provide the following materials:  (See Application Face Sheet)

  1. The NIH grant application for consideration of an End Duchenne Grant Award
  2. The NIH Summary Statement to the grant application
  3. A response to NIH reviewers comments/concerns (optional)
  4. A proposal to PPMD for funding (see online application):
    • Introduction: narrative describing the significance of the project, outlining the specific work scope and approach for bridge funding--what specific aims (experimentations) would be performed and the rationale for choice of experiments to address issues identified in NIH review and to advance progress of the project, keeping within the budget frame of 80% funding of first year direct costs.
    • Research methods: Provide details of methods for any experiments not already outlined in NIH grant proposal. New experimentation may be proposed to address issues raised in NIH grant review.
    • Facilities/new personnel (CV) if any additions made from NIH applications
    • Anticipated time frame for submission of revised grant application to NIH
    • Budget for proposed research (up to $150,000 not to exceed direct costs of first year NIH grant)

An Application Face Sheet should accompany the proposal.

Application Submission

For more information regarding this grant opportunity, please contact Sharon Hesterlee, Ph.D., Vice President Research at or call 520-444-4462.

Number of awards each cycle is dependent on the number of applications, outcome of review and the availability of funds. PPMD is not obligated to make awards following each grant cycle.

Review Process

The review of the End Duchenne Prize Grant addresses these key issues:

  1. Significance: Does the proposal meet the objectives of the EndDuchenne Grant Award Program to facilitate promising research towards new therapeutics for Duchenne muscular dystrophy? Does the proposal address an approach to developing a new treatment strategy that is not currently being investigated?
  2. Scientific merit of the research plan: Given the NIH review and response of the investigator, is the work scope proposed in the PPMD application reasonable and appropriate to address the issues of the NIH review and enhance success in resubmission? Are there other experiments for the investigator to consider?
  3. Resources and/or expertise in place to perform the work?
  4. Budget-appropriateness for work scope proposed

The review process will maintain strict confidentiality and attend to issues of conflict of interests. Applicants will be informed of disposition of the grant within a short time frame following the review. PPMD will make the final award decisions, in its sole discretion.

For more information on the End Duchenne Grant Award Program, please contact Sharon Hesterlee at 520-444-4462 or

Related links

End Duchenne GAP Policy Manual
Apply for Funding

Facebook YouTube Twitter

Our family-centered approach is at the heart of everything we do. Learn more.